| CMND |
Clearmind Medicine Inc. |
72%
|
Reciprocal relationship from CMND graph: Reciprocal relationship from SPRC graph: NOTE 7:- INVESTMENT IN ASSOCIATES MitoCareX Transaction On March 10, 2022, the Company entered into a Founders and In… |
| CMND |
Clearmind Medicine Inc. |
72%
|
NOTE 7:- INVESTMENT IN ASSOCIATES MitoCareX Transaction On March 10, 2022, the Company entered into a Founders and Investment Agreement with Dr. Alon Silberman (the “MitoCareX Agreement”). Pursuant t… |
| ESLT |
Elbit Systems Ltd. |
72%
|
Reciprocal relationship from ESLT graph: Reciprocal relationship from SPRC graph: Reciprocal relationship from ESLT graph: Reciprocal relationship from SPRC graph: aceutical product candidates in the… |
| ESLT |
Elbit Systems Ltd. |
72%
|
aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including restricted deposits, was $4.6 million. Our cash and cash equivalents position is … |
| FRSX |
Foresight Autonomous Holdings Ltd. |
72%
|
Reciprocal relationship from FRSX graph: Reciprocal relationship from SPRC graph: aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including… |
| FRSX |
Foresight Autonomous Holdings Ltd. |
72%
|
aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including restricted deposits, was $4.6 million. Our cash and cash equivalents position is … |
| JFBR |
Jeffs Brands Ltd |
72%
|
Reciprocal relationship from JFBR graph: rresponding adjustment in revenues. The Group recorded an allowance for returns in the amounts of $ 12 thousand and $ 21 thousand as of December 31, 2024, and… |
| NEXRW |
NEXRW |
72%
|
aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including restricted deposits, was $4.6 million. Our cash and cash equivalents position is … |
| NEXRW |
NEXRW |
72%
|
Reciprocal relationship from NEXRW graph: Reciprocal relationship from SPRC graph: aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, includin… |
| NNDM |
Nano Dimension Ltd. |
72%
|
Reciprocal relationship from NNDM graph: Reciprocal relationship from SPRC graph: aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including… |
| NNDM |
Nano Dimension Ltd. |
72%
|
aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including restricted deposits, was $4.6 million. Our cash and cash equivalents position is … |
| NXTS |
NXTS |
72%
|
NOTE 7:- INVESTMENT IN ASSOCIATES MitoCareX Transaction On March 10, 2022, the Company entered into a Founders and Investment Agreement with Dr. Alon Silberman (the “MitoCareX Agreement”). Pursuant t… |
| NXTS |
NXTS |
72%
|
Reciprocal relationship from NXTS graph: Reciprocal relationship from SPRC graph: NOTE 7:- INVESTMENT IN ASSOCIATES MitoCareX Transaction On March 10, 2022, the Company entered into a Founders and In… |
| PRZO |
ParaZero Technologies Ltd. |
72%
|
aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including restricted deposits, was $4.6 million. Our cash and cash equivalents position is … |
| PRZO |
ParaZero Technologies Ltd. |
72%
|
Reciprocal relationship from PRZO graph: Reciprocal relationship from SPRC graph: Reciprocal relationship from PRZO graph: Reciprocal relationship from SPRC graph: aceutical product candidates in the… |
| RVSN |
Rail Vision Ltd. |
72%
|
aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including restricted deposits, was $4.6 million. Our cash and cash equivalents position is … |
| RVSN |
Rail Vision Ltd. |
72%
|
Reciprocal relationship from RVSN graph: Reciprocal relationship from SPRC graph: aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including… |
| AUTOMAX-MOTORS-LTD |
AUTOMAX-MOTORS-LTD |
62%
|
e required by the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies, domestic or foreign, to perform clinical, nonclinical or other types of studies in addition to those th… |
| CAPITAL-POINT-LTD |
CAPITAL-POINT-LTD |
62%
|
l to meet all applicable Nasdaq Capital Market requirements, Nasdaq could delist our Ordinary Shares, which could adversely affect the market liquidity of our Ordinary Shares and the market price of … |
| CLINIQUANTUM-LTD |
CLINIQUANTUM-LTD |
62%
|
ire in the near term. Upon the expiration of a patent, the protections afforded by such patent cease and third parties may be free to manufacture, use, sell, or import products or technologies that w… |
| EVERO-HEALTH-LTD |
EVERO-HEALTH-LTD |
62%
|
l to meet all applicable Nasdaq Capital Market requirements, Nasdaq could delist our Ordinary Shares, which could adversely affect the market liquidity of our Ordinary Shares and the market price of … |
| XYLO-TECHNOLOGIES-LTD |
XYLO-TECHNOLOGIES-LTD |
62%
|
ard-looking statements. Any forward-looking statements in this Annual Report are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements… |
| YISSUM-RESEARCH-DEVELOPMENT-COMPANY |
YISSUM-RESEARCH-DEVELOPMENT-COMPANY |
62%
|
NOTE 15:- EMPLOYEE BENEFIT LIABILITIES Employee benefits consist of short-term benefits and post-employment benefits. Post-employment benefits: According to the labor laws and the Israeli Severance P… |
